254 related articles for article (PubMed ID: 11870534)
1. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients.
Pérez-Tenorio G; Stål O;
Br J Cancer; 2002 Feb; 86(4):540-5. PubMed ID: 11870534
[TBL] [Abstract][Full Text] [Related]
2. Bad expression predicts outcome in patients treated with tamoxifen.
Cannings E; Kirkegaard T; Tovey SM; Dunne B; Cooke TG; Bartlett JM
Breast Cancer Res Treat; 2007 Apr; 102(2):173-9. PubMed ID: 17004114
[TBL] [Abstract][Full Text] [Related]
3. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
[TBL] [Abstract][Full Text] [Related]
4. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
5. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
6. AKT activation predicts outcome in breast cancer patients treated with tamoxifen.
Kirkegaard T; Witton CJ; McGlynn LM; Tovey SM; Dunne B; Lyon A; Bartlett JM
J Pathol; 2005 Oct; 207(2):139-46. PubMed ID: 16088978
[TBL] [Abstract][Full Text] [Related]
7. Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome.
Vestey SB; Sen C; Calder CJ; Perks CM; Pignatelli M; Winters ZE
Eur J Cancer; 2005 May; 41(7):1017-25. PubMed ID: 15862750
[TBL] [Abstract][Full Text] [Related]
8. Akt kinases in breast cancer and the results of adjuvant therapy.
Stål O; Pérez-Tenorio G; Akerberg L; Olsson B; Nordenskjöld B; Skoog L; Rutqvist LE
Breast Cancer Res; 2003; 5(2):R37-44. PubMed ID: 12631397
[TBL] [Abstract][Full Text] [Related]
9. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
[TBL] [Abstract][Full Text] [Related]
10. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):511S-5S. PubMed ID: 12538508
[TBL] [Abstract][Full Text] [Related]
11. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin.
Pohl G; Rudas M; Dietze O; Lax S; Markis E; Pirker R; Zielinski CC; Hausmaninger H; Kubista E; Samonigg H; Jakesz R; Filipits M
J Clin Oncol; 2003 Oct; 21(19):3594-600. PubMed ID: 14512390
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
13. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.
Lim SJ; Lopez-Berestein G; Hung MC; Lupu R; Tari AM
Oncogene; 2000 Dec; 19(54):6271-6. PubMed ID: 11175341
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer.
Pérez-Tenorio G; Berglund F; Esguerra Merca A; Nordenskjöld B; Rutqvist LE; Skoog L; Stål O
Int J Oncol; 2006 May; 28(5):1031-42. PubMed ID: 16596219
[TBL] [Abstract][Full Text] [Related]
15. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients.
Tokunaga E; Kimura Y; Oki E; Ueda N; Futatsugi M; Mashino K; Yamamoto M; Ikebe M; Kakeji Y; Baba H; Maehara Y
Int J Cancer; 2006 Jan; 118(2):284-9. PubMed ID: 16049961
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.
Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Ellis IO; Green AR
Breast Cancer Res Treat; 2011 Jun; 127(2):407-16. PubMed ID: 20617378
[TBL] [Abstract][Full Text] [Related]
17. Heregulin regulation of Akt/protein kinase B in breast cancer cells.
Liu W; Li J; Roth RA
Biochem Biophys Res Commun; 1999 Aug; 261(3):897-903. PubMed ID: 10441522
[TBL] [Abstract][Full Text] [Related]
18. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients.
Dillon MF; Stafford AT; Kelly G; Redmond AM; McIlroy M; Crotty TB; McDermott E; Hill AD; Young LS
Endocr Relat Cancer; 2008 Sep; 15(3):745-53. PubMed ID: 18469157
[TBL] [Abstract][Full Text] [Related]
20. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
